Zurich-Schlieren, March 01, 2017.  Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today announced that it will present at at the Cowen and Company 37th Annual Healthcare Conference on Tuesday, March 07, 2017

Research & Development: MP0250: Phase 2 in multiple myeloma: study approved by BfArM in Germany and ongoing regulatory submissions in other countries; first safety data expected in 2017 and efficacy data in 2018 MP0250: Additional Phase 2 trial for solid tumor indication to be submitted in 2017;

Zurich-Schlieren, February 9, 2017.  Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin®* therapies, today announces that the Board of Directors has decided to propose Gwen Fyfe, MD, for election as member of the Board of

Zurich-Schlieren, January 04, 2017.  Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today announced that it will present at the 35th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2017 at